Champions Oncology (STU:2I3) Long-Term Capital Lease Obligation : €4.83 Mil (As of Jan. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Champions Oncology Long-Term Capital Lease Obligation?

Champions Oncology's Long-Term Capital Lease Obligation for the quarter that ended in Jan. 2025 was €4.83 Mil.

Champions Oncology's quarterly Long-Term Capital Lease Obligation declined from Jul. 2024 (€5.29 Mil) to Oct. 2024 (€4.93 Mil) and declined from Oct. 2024 (€4.93 Mil) to Jan. 2025 (€4.83 Mil).

Champions Oncology's annual Long-Term Capital Lease Obligation declined from Apr. 2022 (€7.79 Mil) to Apr. 2023 (€6.74 Mil) and declined from Apr. 2023 (€6.74 Mil) to Apr. 2024 (€5.68 Mil).

Champions Oncology Long-Term Capital Lease Obligation Historical Data

The historical data trend for Champions Oncology's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Champions Oncology Long-Term Capital Lease Obligation Chart

Champions Oncology Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

2.92

7.34

7.79

6.74

5.68

Champions Oncology Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															5.91	5.68	5.29	4.93	4.83

Champions Oncology (STU:2I3) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Champions Oncology Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Champions Oncology's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Champions Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Champions Oncology Inc (STU:2I3) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

CSBR:USA

Address

One University Plaza, Suite 307, Hackensack, NJ, USA, 07601

Website

https://www.championsoncology.com

Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.

Champions Oncology Headlines

No Headlines